These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21378155)

  • 1. Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.
    Chan DT; Watts GF; Irish AB; Dogra GK
    Nephrol Dial Transplant; 2011 Nov; 26(11):3543-9. PubMed ID: 21378155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
    Dogra G; Irish A; Chan D; Watts G
    Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
    Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes.
    Yilmaz MI; Stenvinkel P; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Altun B; Yenicesu M; Carrero JJ
    Nephrol Dial Transplant; 2011 Nov; 26(11):3537-43. PubMed ID: 21378154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-diabetes and arterial stiffness in uraemic patients.
    Hornum M; Clausen P; Kjaergaard J; Hansen JM; Mathiesen ER; Feldt-Rasmussen B
    Nephrol Dial Transplant; 2010 Apr; 25(4):1218-25. PubMed ID: 19846393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney transplantation improves arterial function measured by pulse wave analysis and endothelium-independent dilatation in uraemic patients despite deterioration of glucose metabolism.
    Hornum M; Clausen P; Idorn T; Hansen JM; Mathiesen ER; Feldt-Rasmussen B
    Nephrol Dial Transplant; 2011 Jul; 26(7):2370-7. PubMed ID: 21097648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD.
    Dogra G; Irish A; Chan D; Watts G
    Am J Kidney Dis; 2006 Dec; 48(6):926-34. PubMed ID: 17162147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
    Sidhu JS; Cowan D; Kaski JC
    Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
    Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
    Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
    J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity.
    Kar P; Laight D; Rooprai HK; Shaw KM; Cummings M
    Diabet Med; 2009 May; 26(5):526-31. PubMed ID: 19646193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
    Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
    Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
    Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
    Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
    Lazich I; Sarafidis P; de Guzman E; Patel A; Oliva R; Bakris G
    Diabetes Obes Metab; 2012 Feb; 14(2):181-6. PubMed ID: 21955403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD.
    Zoungas S; Cameron JD; Kerr PG; Wolfe R; Muske C; McNeil JJ; McGrath BP
    Am J Kidney Dis; 2007 Oct; 50(4):622-30. PubMed ID: 17900462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-18 is involved in vascular injury in end-stage renal disease patients.
    Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
    Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.